Nautilus Biotechnology, Inc. (NAUT)

NASDAQ: NAUT · IEX Real-Time Price · USD
-0.06 (-2.09%)
Nov 28, 2023, 4:00 PM EST - Market closed

Company Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.

It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

The company was incorporated in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology, Inc.
Nautilus Biotechnology logo
Country United States
Founded 2016
Industry Biotechnology
Sector Healthcare
Employees 160
CEO Sujal M. Patel

Contact Details

2701 Eastlake Ave East
Seattle, Washington 98102
United States
Phone 206-333-2001

Stock Details

Ticker Symbol NAUT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001808805
CUSIP Number 63909J108
ISIN Number US63909J1088
Employer ID 98-1541723
SIC Code 3826

Key Executives

Name Position
Sujal M. Patel Co-Founder, Chief Executive Officer, President, Secretary and Director
Dr. Parag Mallick Ph.D. Co-Founder, Chief Scientist and Director
Matthew B. Murphy ESQ. General Counsel
Anna Mowry Chief Financial Officer and Treasurer
Mary E. Godwin Senior Vice President of Operations
Chris Blessington Vice President of Corporate Marketing and Communications
Gwen E. Weld Chief People Officer
Nick A. Nelson Chief Business Officer and Senior Vice President of Bus. Development
Dr. Subra Sankar Ph.D. Senior Vice President of Product Development

Latest SEC Filings

Date Type Title
Nov 22, 2023 424B3 Prospectus
Nov 17, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Oct 31, 2023 10-Q Quarterly Report
Oct 31, 2023 8-K Current Report
Aug 2, 2023 10-Q Quarterly Report
Aug 2, 2023 8-K Current Report
Jun 15, 2023 8-K Current Report
May 2, 2023 10-Q Quarterly Report
May 2, 2023 8-K Current Report
Apr 27, 2023 ARS Filing